Roivant's lung disease drug fails mid-stage trial (updated)

Roivant Sciences

03/12/2024 12:16

(Adds details in paragraphs 2,3 and shares in paragraph 4)
       Dec 3 (Reuters) - Roivant  ROIV.O  said on Tuesday its
drug did not meet the main goal in a mid-stage trial evaluating
it in patients with a type of lung disease.
    The drugmaker said it will discontinue further development
of the drug, namilumab, for the treatment of chronic active
pulmonary sarcoidosis.
    It is a rare disease that causes lumps of inflammatory cells
to form in the lungs and other organs, leading to tissue damage
and organ dysfunction.
    Shares of Roivant fell 1.3% in premarket trading.

 (Reporting by Christy Santhosh in Bengaluru; Editing by
Shinjini Ganguli)
 ((Christy.Santhosh@thomsonreuters.com;))